## AMENDMENTS TO THE CLAIMS

Please amend claims 80, 83, 89, 95, 98 and 104, and cancel claims 82, 87, 94, 96, 103 and 105, without prejudice or disclaimer, so that the pending claims are as follows:

1-79. (Canceled).

80. (Currently amended) A sustained-release dosage form, comprising oxymorphone ~~or a~~ salt ~~thereof~~, a hydrophilic polymer, an alkylcellulose, a binder, and a diluent;
wherein said dosage form provides a therapeutic effect for about 12 hours or more.

81. (Previously presented) The sustained-release dosage form of claim 80, wherein the dosage form contains granules having a diameter from about 0.1 mm to about 3 mm.

82. (Canceled).

83. (Currently amended) The sustained-release dosage form of claim 80, ~~further comprising~~ wherein the alkylcellulose is ethylcellulose.

84. (Previously presented) The sustained-release dosage form of claim 80, wherein the dosage form is in the form of a tablet.

85. (Previously presented) The sustained-release dosage form of claim 80, wherein the dosage form is in the form of a capsule.

86. (Previously presented) The sustained-release dosage form of claim 80, wherein the dosage form is in the form of a matrix.

87. (Canceled).

88. (Previously presented) The sustained-release dosage form of claim 80, wherein the dosage form provides a therapeutic effect for about 24 hours or more.

89. (Currently amended) A sustained-release dosage form, made by the process comprising: (a) mixing oxymorpbone ~~or a~~ salt ~~thereof~~ with a hyrodrophilic polymer, an alkylcellulose, a binder, and a diluent; (b) subjecting the mixture to shear to form granules; and (c) incorporating the granules into a dosage form;

wherein said dosage form provides a therapeutic effect for about 12 hours or more.

90. (Previously presented) The process of claim 89, wherein the granules have a diameter from about 0.1 mm to about 3 mm.

91. (Previously presented) The process of claim 89, wherein step (c) comprises incorporating the granules into a tablet.

92. (Previously presented) The process of claim 89, wherein step (c) comprises incorporating the granules into a capsule.

93. (Previously presented) The process of claim 89, wherein the dosage form is a matrix.

94. (Canceled).

95. (Currently amended) The process of claim 89, wherein ~~step (a) further comprises mixing oxymorphone or a salt thereof with~~ the alkylcellulose is ethylcellulose.

96. (Canceled).

97. (Previously presented) The process of claim 89, wherein the dosage form provides a therapeutic effect for about 24 hours or more.

98. (Currently amended) A process of making a sustained-release dosage form that provides a therapeutic effect for about 12 hours or more,

which process ~~comprising~~ comprises:

(a) mixing oxymorphone ~~or a~~ salt ~~thereof~~ with a hydrophilic polymer, an alkylcellulose, a binder, and a diluent;

(b) subjecting the mixture to shear to form granules; and

(c) incorporating the granules into a dosage form.

99. (Previously presented) The process of claim 98, wherein the granules have a diameter from about 0.1 mm to about 3mm.

100. (Previously presented) The process of claim 98, wherein step (c) comprises incorporating the granules into a tablet.

101. (Previously presented) The process of claim 98, wherein step (c) comprises incorporating the granules into a capsule.

102. (Previously presented) The process of claim 98, wherein the dosage form is a matrix.

103. (Canceled).

104. (Currently amended) The process of claim 98, wherein ~~step (a) further comprises mixing oxymorphone or a salt thereof with~~ the alkylcellulose is ethylcellulose.

105. (Canceled).

106. (Previously presented) The process of claim 98, wherein the dosage form provides a therapeutic effect for about 24 hours or more.

107-142. (Canceled).

* * * * *